KFP H019
Alternative Names: H 019; KFP-H019Latest Information Update: 07 Oct 2021
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Exportin 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Sep 2021 Preclinical trials in Cancer (Late-stage disease) in China (unspecified route) before September 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)
- 28 Sep 2021 Jiangsu Carephar Pharmaceutical plans to submit IND application for Cancer in USA and China in 2022 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)